Press Releases

Jounce Therapeutics, Inc. at the H.C. Wainwright BioConnect 2021 Conference
1/11/21 6:00 AM EST
Date Title  
Jan 13, 2021
- INNATE is a robust Phase 1 study designed to dose escalate quickly and demonstrate proof of concept for JTX-8064 monotherapy and PD-1i combinations - - Tumor-specific expansion cohorts to include PD-(L)1i resistant and sensitive tumors and  PD-(L)1i naïve and experienced patients - CAMBRIDGE,
Jan 8, 2021
CAMBRIDGE, Mass. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will present at two upcoming investor